Dana Narvaez, MD

Proud to receive the IDEA Award from @ASCO @ConquerCancerFd . Thank you for supporting young oncologists from around the world working to make a difference

Science and Access: A Global Oncology Perspective - Dana Narvaez (@narvaezdanap) @DrSGraff @GParkinsonMD oncodaily.com/voices/dana-na… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

✨Excited to share our new review on post-CDK4/6i treatment sequencing in HR+/HER2− metastatic breast cancer is out in @IJMS_MDPI 🔬 🧬Exploring biomarker-driven strategies and emerging therapies mdpi.com/1422-0067/26/2…

#ESMO25 Managing HR+/HER2– mBC in 2025 💬An update is likely following the evERA and VIKTORIA-1 trials From Dr. William Gradishar's presentation👇

Stay tuned for our Volunteer Led Webinar, Oct 24, 12:00 CST. @JasmineKambojMD @narvaezdanap @yuan_ruiling @WadeSwenson @ErulEnes @DrYukselUrun @AbiSivaMD @oncodaily @oncologyCOA @HemOncWomenDocs @HemOncFellows @IMG_Oncologists @ASCO #Policy @USOResearch

The most powerful tool of your mind is not its capacity to know, but its ability to question.

🚨 Out now in @TAMedOncol! 💡 Our LATAM study reveals strong heterogeneity in treatment decisions for young women with HR+/HER2– early breast cancer — influenced by physician specialty, gender & resource availability. 17 countries 🇦🇷🇲🇽🇪🇨🇨🇴🇻🇪🇵🇾🇨🇱🇵🇪🇨🇺 🔗 doi.org/10.1177/175883…

Our editorial comment on the clinical utility and current challenges of ctDNA surveillance in breast cancer is out in @TAMedOncol doi.org/10.1177/175883… @fwaisberg1

✨ The power of engagement Young oncologists building bridges of science, purpose, and collaboration. 🤍🌍 #youngcommittee #comitejoven #breastcancer #patagonia @SUMAargentina @aaoncoclinica

HR+/HER2– advanced breast cancer after CDK4/6i progression: ideal scenarios vs real-world access to therapies in global oncology 📍 Patagonian Breast Cancer Congress 🎤 Talk by Dr. @ggabuin @SUMAargentina @aaoncoclinica

ctDNA in Early Breast Cancer at the Patagonian Breast Cancer Congress What do we need to understand? Talk by Dr. Carlos Barrios @aaoncoclinica @SUMAargentina @LACOG_group

It’s hard to believe it’s been 20 years since Steve told Stanford graduates to stay hungry and stay foolish. His powerful advice still rings true, and I hope it helps guide this year’s new grads as they begin their journey to become tomorrow’s leaders. stevejobsarchive.com/exhibits/stay-…

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) shorturl.at/ZnMI5

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 🔗nejm.org/doi/full/10.10… 👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) @OncoAlert #OncoAlertAF #BreastCancer #RadOnc

A few quick 📸 of the @ASCO @ConquerCancerFd #IDEA Grantees over their visit @BrownUCancer @BrownMedicine @BrownUnivHealth #globaloncology

Today at Brown, we had the honor of listening to Dr. @DrSGraff powerful talk on influential leadership. I deeply admire her ability to lead with both scientific excellence and profound human connection @ConquerCancerFd @BrownUCancer

#ASCO25 Dr. Mukhtar presented I-SPY2 data showing ctDNA as a potential predictor of nodal burden after neoadjuvant therapy. Promising steps toward more personalized, biology-driven treatment decisions.

@YAbdouMD @paolazagam @KalinskyKevin @ConquerCancerFd Agree! Fan club here 🙌🏼

@paolazagam @KalinskyKevin @ConquerCancerFd 💯 @KalinskyKevin is the best 🤩

It was a great honor to meet @KalinskyKevin,amazing oncologist and beautiful person! Thanks a lot for your and dr Keir support, endorsing my ASCO conquer cancer merit awar🏅. Great and interesting presentation of NATALEE trial by age and menopausal! @ConquerCancerFd #ASCO25

@Martin_AngelMD @OfficialDrMaj @DrDanielHeng @ZarbaMartin1 👏👏

Happy to collaborate with #IMDC team Thanks @OfficialDrMaj @DrDanielHeng @ZarbaMartin1 #ASCO25

Happening Now! #ASCO25 Poster Session 👉 Use of baseline plasma circulating tumor DNA (#ctDNA) to predict duration of endocrine therapy and CDK4/6 inhibitor therapy and to analyze intrinsic vs acquired #EndocrineResistance. @PietroDePlacido 📍Abs 1075 | Poster Bd 54 | Jun 2, 9-12 PM | Hall A

📍ASCO25 – Day 3 Powerful presentation by Dr Turner on the long-awaited SERENA-6 trial. Dr @AngieDemichele delivered a super interesting analysis of its clinical utility Is ctDNA redefining the landscape of breast cancer care? Exciting times ahead for precision oncology 👏